This review highlights literature pertinent to chimerism analysis in the context of
hematopoietic cell transplantation (HCT). We also conducted a survey of testing practices of …

Although allogeneic hematopoietic cell transplantation (allo-HCT) is currently the standard
curative treatment of acute leukemia, relapse remains unacceptably high. Measurable …

Chimerism refers to the relative proportion of donor and recipient DNA after hematopoietic
stem cell transplantation (HSCT) and its quantitative follow-up is of great clinical utility in this …

Acute Myeloid Leukemia (AML) is the commonest indication for allogeneic stem cell
transplantation (allo-SCT) worldwide. The increasingly important role of allo-SCT in the …

Background Minimal residual disease (MRD) and hematopoietic chimerism testing
influences clinical decision and therapeutic intervention in patients after allogeneic stem cell …

Recipient–donor chimerism is routinely analyzed after allogeneic hematopoietic stem cell
transplantation (HSCT) to monitor engraftment and graft rejection. For malignancies …

Chimerism testing is used to monitor engraftment and risk of relapse after allogeneic
hematopoietic stem cell transplantation for hematologic malignancies. Although short …

Primarily due to recent advances of detection techniques, microchimerism (the proportion of
minor variant population is below 1%) has recently gained increasing attention in the field of …

Donor lymphocyte infusion (DLI) is a standard of care for relapse of acute myeloid leukemia
after allogeneic hematopoietic stem cell transplantation. Currently it is poorly understood …

Chimerism monitoring after allogenic Hematopoietic Cell Transplantation (allo-HCT) is
critical to determine how well donor cells have engrafted and to detect relapse for early …